Get started
Author

Christopher D. Carlson

Trial of Solanezumab for Mild Dementia Due to Alzheimer’s Disease
2018 · Lawrence S. Honig, Bruno Vellas, et al. · New England Journal of Medicine · 1,048
PDF
Phase 3 solanezumab trials: Secondary outcomes in mild Alzheimer's disease patients
2015 · Eric R. Siemers, Karen L. Sundell, et al. · Alzheimer s & Dementia · 369
PDF
Efficacy and Safety of Atomoxetine in Adolescents with Attention-Deficit/Hyperactivity Disorder and Major Depression
2007 · The Atomoxetine ADHD and Comorbid MDD Study Group:, Mark E. Bangs, et al. · Journal of Child and Adolescent Psychopharmacology · 103
Effects of Antipsychotic Drugs on Ito, INa, Isus, IK1, and hERG: QT Prolongation, Structure Activity Relationship, and Network Analysis
2006 · William J. Crumb, Sean Ekins, et al. · Pharmaceutical Research · 92
Amantadine for weight gain associated with olanzapine treatment
2004 · Walter Deberdt, Andrew Winokur, et al. · European Neuropsychopharmacology · 85
Prevalence of asymptomatic vasogenic edema in pretreatment Alzheimer's disease study cohorts from phase 3 trials of semagacestat and solanezumab
2011 · Christopher Carlson, Wahiba Estergard, et al. · Alzheimer s & Dementia · 78
Evaluation of Insulin Sensitivity in Healthy Volunteers Treated with Olanzapine, Risperidone, or Placebo: A Prospective, Randomized Study Using the Two-Step Hyperinsulinemic, Euglycemic Clamp
2003 · Margaret Sowell, Nitai Mukhopadhyay, et al. · The Journal of Clinical Endocrinology & Metabolism · 69
PDF
Amyloid‐related imaging abnormalities from trials of solanezumab for Alzheimer's disease
2016 · Christopher Carlson, Eric Siemers, et al. · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · 66
PDF
Stimulation of tyrosine hydroxylase gene transcription rate by nicotine in rat adrenal medulla.
1991 · L H Fossom, C D Carlson, et al. · Molecular Pharmacology · 59
An Integrated Analysis of Acute Treatment-Emergent Extrapyramidal Syndrome in Patients With Schizophrenia During Olanzapine Clinical Trials
2003 · Christopher D. Carlson, Patrizia A. Cavazzoni, et al. · The Journal of Clinical Psychiatry · 58
Diabetes mellitus and antipsychotic treatment in the United Kingdom
2005 · Christopher Carlson, Kenneth Hornbuckle, et al. · European Neuropsychopharmacology · 49
Delayed‐start analysis: Mild Alzheimer's disease patients in solanezumab trials, 3.5 years
2015 · Hong Liu‐Seifert, Eric Siemers, et al. · Alzheimer s & Dementia Translational Research & Clinical Interventions · 48
PDF
Lipopolysaccharide induces substance P in sympathetic ganglia via ganglionic interleukin-1 production
1994 · Annette M. Shadiak, Christopher D. Carlson, et al. · Journal of Neuroimmunology · 29
Retrospective analysis of risk factors in patients with treatment-emergent diabetes during clinical trials of antipsychotic medications
2004 · Patrizia Cavazzoni, Nitai Mukhopadhyay, et al. · The British Journal of Psychiatry · 26
PDF
Regulation of Cytokine Secretion and Amyloid Precursor Protein Processing by Proinflammatory Amyloid Beta (Aβ)
2000 · BRUCE D. GITTER, LEONARD N. BOGGS, et al. · Annals of the New York Academy of Sciences · 21
Interleukin-1β increases leukemia inhibitory factor mRNA levels through transient stimulation of transcription rate
1996 · Christopher D. Carlson, Yuchen Bai, et al. · Glia · 21
Human Amylin Stimulates Inflammatory Cytokine Secretion from Human Glioma Cells
2000 · Bruce D. Gitter, Laura M. Cox, et al. · NeuroImmunoModulation · 19
Interleukin-1 involvement in the induction of leukemia inhibitory factor mRNA expression following axotomy of sympathetic ganglia
1996 · Christopher D. Carlson, Yuchen Bai, et al. · Journal of Neuroimmunology · 18
Activation of acidic sphingomyelinase and protein kinase C is required for IL-1 induction of LIF mRNA in a schwann cell line
1996 · Christopher D. Carlson, Ronald P. Hart · Glia · 16
P.2.132 A retrospective cohort study of diabetes mellitus and antipsychotic treatment in the United Kingdom
2004 · P. Cavazzoni, K. Hornbuckle, et al. · European Neuropsychopharmacology · 10
Increased Cell‐Cell Contact Stimulates the Transcription Rate of the Tyrosine Hydroxylase Gene in Rat Pheochromocytoma PC 18 Cells
1994 · Christopher D. Carlson, A. William Tank · Journal of Neurochemistry · 7
[p1–042]: Plasma Pharmacokinetics and Pharmacodynamics of Solanezumab in Mild and Moderate Ad Patients
2017 · Brian A. Willis, Lisa R. Ferguson‐Sells, et al. · Alzheimer s & Dementia · 5
PDF
O1–06–04: Efficacy of solanezumab in patients with mild or moderate Alzheimer's disease: Pooled analyses findings from two phase III studies
2013 · Christopher Carlson, Karen Sundell, et al. · Alzheimer s & Dementia · 3
PDF
P4‐472: Vasogenic edema in the setting of ß‐amyloid lowering therapy, adverse event: what is it and how is it detected?
2011 · Jerome Barakos, Christopher Carlson, et al. · Alzheimer s & Dementia · 3
PDF
[P1–044]: SAFETY OF SOLANEZUMAB IN PHASE 3 STUDIES IN INDIVIDUALS WITH MILD ALZHEIMER's DISEASE DEMENTIA
2017 · Christopher D. Carlson, Greg Anglin, et al. · Alzheimer s & Dementia · 2
Works count: 36
Citation count: 2,309
H-index: 18
I10-index: 20
Year
Topic
Type